Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Jean-Yves Loze"'
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
BackgroundCurrent guidelines recommend intramuscular botulinum toxin type A (BoNT-A) injection as first-line treatment for spasticity, a frequent and impairing feature of various central nervous system (CNS) lesions such as stroke. Patients with spas
Externí odkaz:
https://doaj.org/article/87d748b0ac2c46eb927b31fd9ed063ef
Publikováno v:
Toxins, Vol 15, Iss 4, p 280 (2023)
There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients
Externí odkaz:
https://doaj.org/article/3c58569041704b258f4dff3f3db8ce57
Autor:
Maxine X. Patel, Nawal Bent-Ennakhil, Christophe Sapin, Sylvie di Nicola, Jean-Yves Loze, Anna-Greta Nylander, Stephan Heres
Publikováno v:
BMC Psychiatry, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background Prescription rates for long-acting injectable (LAI) antipsychotic formulations remain relatively low in Europe despite improved adherence over alternative oral antipsychotic treatments. This apparent under-prescription of LAI anti
Externí odkaz:
https://doaj.org/article/b9eabd8fe0344e728550d897f03ebf99
Autor:
Alexis Schnitzler, Clément Dince, Andreas Freitag, Ike Iheanacho, Kyle Fahrbach, Louis Lavoie, Jean-Yves Loze, Anne Forestier, David Gasq
Publikováno v:
Toxins, Vol 14, Iss 11, p 734 (2022)
Disabling limb spasticity can result from stroke, traumatic brain injury or other disorders causing upper motor neuron lesions such as multiple sclerosis. Clinical studies have shown that abobotulinumtoxinA (AboBoNT-A) therapy reduces upper and lower
Externí odkaz:
https://doaj.org/article/ca0a6c8b7bd746219198db54a343a783
Autor:
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Simon Nitschky Schmidt, Anders Ettrup, Anna Eramo, Karina Hansen, Dieter Naber
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183475 (2017)
Schizophrenia is a chronic disease with negative impact on patients' employment status and quality of life. This post-hoc analysis uses data from the QUALIFY study to elucidate the relationship between work readiness and health-related quality of lif
Externí odkaz:
https://doaj.org/article/b5d30494aa3d4448b36c28ade08cdac6
Autor:
Anne de Jong Laird, Stephan Heres, Pedro Such, Paul Robinson, Anna Greta Nylander, John F.P. Bridges, Jean Yves Loze, Elcie Chan, Kaitlan Amos, Kathleen Beusterien
Publikováno v:
Current Medical Research and Opinion. 33:2129-2136
This study sought to evaluate a new stated-preference instrument to prioritize multiple treatment goals among people with recent onset schizophrenia.A draft survey instrument was developed to assess preferences for 13 key treatment goals that were id
Autor:
Jean-Yves Loze, Anna-Greta Nylander, Ross A. Baker, Peter Hertel, Dieter Naber, Henrik Steen Andersen, K. Hansen, Carlos Forray, Steven G. Potkin, Timothy Peters-Strickland, M. Beillat, Christophe Sapin, Anna Eramo
Publikováno v:
International Clinical Psychopharmacology
Supplemental Digital Content is available in the text.
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole on
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole on
Autor:
Carlos Forray, Ross A. Baker, Dieter Naber, Anna-Greta Nylander, Steven G. Potkin, Timothy Peters-Strickland, M. Beillat, Simon Nitschky Schmidt, Christophe Sapin, Peter Hertel, Anna Eramo, K. Hansen, Jean-Yves Loze
Publikováno v:
International Journal of Neuropsychopharmacology
Potkin, SG; Loze, J-Y; Forray, C; Baker, RA; Sapin, C; Peters-Strickland, T; et al.(2017). Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 20(1). doi: 10.1093/ijnp/pyw093. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/6nf259k4
Potkin, SG; Loze, J-Y; Forray, C; Baker, RA; Sapin, C; Peters-Strickland, T; et al.(2017). Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 20(1). doi: 10.1093/ijnp/pyw093. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/6nf259k4
Author(s): Potkin, Steven G; Loze, Jean-Yves; Forray, Carlos; Baker, Ross A; Sapin, Christophe; Peters-Strickland, Timothy; Beillat, Maud; Nylander, Anna-Greta; Hertel, Peter; Nitschky Schmidt, Simon; Eramo, Anna; Hansen, Karina; Naber, Dieter | Abst
Autor:
Maxine X. Patel, Jean Yves Loze, Nawal Bent-Ennakhil, Anna Greta Nylander, Christophe Sapin, Sylvie Di Nicola, Stephan Heres
Publikováno v:
BMC Psychiatry
BMC Psychiatry, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Psychiatry, Vol 20, Iss 1, Pp 1-11 (2020)
Background Prescription rates for long-acting injectable (LAI) antipsychotic formulations remain relatively low in Europe despite improved adherence over alternative oral antipsychotic treatments. This apparent under-prescription of LAI antipsychotic
Autor:
Anna-Greta Nylander, Jean-Yves Loze, A. Rouleau, Benedicto Crespo-Facorro, Sara Steeves, Richard Newton, Henrike K Resemann
Publikováno v:
NPJ Schizophr. 2018 Oct 15;4(1):21
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
npj Schizophrenia, Vol 4, Iss 1, Pp 1-10 (2018)
NPJ Schizophrenia
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
npj Schizophrenia, Vol 4, Iss 1, Pp 1-10 (2018)
NPJ Schizophrenia
Schizophrenia is a debilitating psychiatric disorder and patients experience significant comorbidity, especially cognitive and psychosocial deficits, already at the onset of disease. Previous research suggests that treatment during the earlier stages